


Volpara Scorecard

Women diagnosed during the earliest stages of breast cancer have better outcomes and survival rates.¹

Volpara® Scorecard™ software provides your breast care team with the insights they need to find cancer earlier.

Easily accessed from the radiologist's workstation, Volpara Scorecard streamlines your workflow to improve clinical decision-making and create a better patient experience.



3 breast cancer risk insights, 1 customizable view

① Volpara® TruDensity™

Automated, objective, volumetric breast density measurements and a breast density category for an objective and consistent assessment²

② Volpara® Risk™*

Tyrer-Cuzick v8 Risk Evaluation Tool to calculate lifetime risk of developing breast cancer³

③ Suspicious findings score**

Machine learning-based analysis to categorize mammograms by the likelihood of the presence of cancerous lesions⁴

* Available as an integration with Volpara® Patient Hub™ software

** Available as an integration with ScreenPoint Medical (Transpara®) or iCAD software

Automatic
density assessment



Lifetime
risk



Suspicious
findings



Personalized
screening approach

References

1. Clinical outcomes in very early breast cancer (≤ 1 cm): A national population based analysis. Mahvish Muzaffar, Abdul Rafeh Naqash, Nasreen A. Vohra, Darla K. Liles, and Jan H. Wong Journal of Clinical Oncology 2017 35:15_suppl, e12034-e12034

2. Gubern-Mérida, A., Kallenberg, M., Platel, B., Mann, R.M., Marti, R. and Karssmeijer, N. (2014) Volumetric Breast Density Estimation from Full-Field Digital Mammograms: A Validation Study. PLoS ONE; 9: e85952

3. Terry, M.B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20, 504–517 (2019).

4. Rodriguez-Ruiz et al., Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study. Eur Radiology. 2019; 29@: pp 4825–4832

BI-RADS is a registered trademark of the American College of Radiology and American College of Radiology Association. Transpara is a registered trademark of ScreenPoint Medical BV. Copyright © Volpara Health Technologies Ltd. 2021. All rights reserved.

Clinical decision support for personalized breast care

Volpara Scorecard is available to radiologists during mammography interpretation as a DICOM Secondary Capture Image. This customizable image also includes these features:

- Volpara® TruRadDose™ and Volpara® TruPressure™ clinical functions provide quality control measures for study dose and compression pressure, respectively.
- Integration allows Volpara Risk and suspicious findings score (of either the Transpara Exam Score or iCAD Case Score) to be included in DICOM Mammography CAD Structured Reports.
- Alerts indicate when the patient meets high-risk thresholds.

Evidence for essential screening

Referring physicians and insurers require evidence of high breast density. Volpara Scorecard's objective, science-based measures help you triage women at high risk to the screening or diagnostic testing essential for better outcomes.

Effective triage for time and cost savings

Personalized screening scores help the radiologist guide a client with high breast density to essential imaging while they're still in the facility, saving an extra trip and the cost of scheduling an additional appointment.

Combined with Volpara® Analytics™ software, Volpara Scorecard assists in identifying populations with high breast density that may require additional services.

➤ FIND OUT MORE

About Volpara Scorecard

To see how the new Volpara Scorecard can support your breast screening program, contact your Volpara Health representative for a live demonstration, or visit our website.

About Volpara

Volpara Health is the leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara remains focused on its mission to help save families from cancer.

Why radiologists choose
Volpara's automated breast
density assessment:

4-6x

Greater risk for clients with dense breasts to develop breast cancer when compared to those with fatty breasts

-30%

Sensitivity in mammographic cancer detection for clients with dense breasts when compared to those with fatty breasts

89%

Average agreement with the VDG category*

96%

Average agreement with Volpara's assessment of fatty (a/b) or dense (c/d)*

*By trained, expert radiologists in clinical practice

57%

Inter-reader
agreement

77%

Intra-reader
agreement

Visual density assessment is not always consistent

Contact

info@volparahealth.com
support@volparahealth.com

US +1 855 607 0478
AUS 1800 370 623
NZ 0800 444 148

Europe +44 203 051 1029
Global +64 4 499 6029

Connect

 @VolparaHealth

 @volpara

 Volpara Health